DermBiont Begins Phase 2 Clinical Trial for Athlete's Foot with a Live Bacterial Topical Probiotic

BOSTON, March 13, 2019 /PRNewswire-PRWeb/ -- DermBiont, an early stage biopharmaceutical company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases has initiated a clinical trial with its lead bacterial therapeutic DBI-001 for the treatment of athlete's foot (T. pedis). The trial will evaluate the safety and tolerability as well as microbiologic and clinical endpoints following the application of three different dosage levels. The results of this trial will enable the start of a second Phase 2 trial in 2019 designed to further define clinical proof of concept in patients with interdigital athlete's foot.

Read More